HC-7366 is under clinical development by Hibercell and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HC-7366’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HC-7366 overview

HC-7366 is under development for the treatment of  clear cell renal cell carcinoma, metastatic renal cell carcinoma, relapsed/refractory acute myelocytic leukemia (AML), myelodysplastic syndrome. The drug candidate contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate in a immediate release oral formulation administered via oral route. It is being developed based on QuAD Platform. It acts by targeting eIF-2-Alpha Kinase GCN2.
It was under development for the treatment of colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), transitional cell carcinoma of the bladder (TCC)  and other solid tumors.

Hibercell overview

Hibercell is a biotechnology company that discovers and develops therapies for treatment of cancer. The company is investigating odetiglucan, an immune modulator candidate that enhances immune functions for the treatment of CRC-based liver Metastasis, pancreatic cancer and liver metastasis. It is also developing adaptive stress response modulator programs, HC-5404 for treatment of renal cell carcinoma, gastric cancer and others advanced solid tumors and HC-7366 to treat head and neck, colorectal and bladder cancer. Hibercell is headquartered in New York, the US.

For a complete picture of HC-7366’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.